We also have demonstrated that MICs over-secrete SDF1 than mature myeloma cells and that treatment of CXCR4 inhibitor, AMD3100, leads to decreased adherence of MICs to MBMSCs, undermined colony formation potential of MICs, and better in vitro and in vivo drug efficacy of Bortezomib(BZM). The gene discussed is CXCL12; the disease is plasma cell myeloma.